CAR-T cell therapy information and care coordination in China
CAR-T Cell Therapy
Learn about approved products, eligibility assessment, treatment timing, and care coordination for international patients in China. Clinical decisions are made by the receiving hospital and treatment team.
Discuss language, time, destination, and itinerary preferences. Do not submit medical records, images, or attachments here.
Timing varies based on manufacturing, inpatient monitoring, response assessment, and the treatment center’s schedule.
Estimated product price per dose, converted at CNY 7 = USD 1.
Testing, cell collection, hospitalization, and other care are quoted separately and subject to individual assessment.
China's Contribution To Global CAR-T Development
One Of The World's Largest CAR-T Clinical Research Ecosystems
A 2026 global analysis identified 1,908 CAR-T clinical studies, including 1,006 in China and 549 in the United States.
Advancing BCMA-Directed CAR-T Therapy For Multiple Myeloma
China currently has three approved BCMA-directed CAR-T products: equecabtagene autoleucel, zevorcabtagene autoleucel, and ciltacabtagene autoleucel. They are approved for patients with relapsed or refractory multiple myeloma who meet the respective eligibility criteria. Ciltacabtagene autoleucel was originally co-developed by China-based Legend Biotech and has since been approved in the United States, European Union, Japan, and China.
First Approval Of A CAR-T Therapy For A Solid Tumor
On June 22, 2026, satricabtagene autoleucel received NMPA approval, becoming the first CAR-T product approved by a regulatory authority for a solid tumor.
Advancing Next-Generation CAR-T Approaches
Research teams in China are studying off-the-shelf allogeneic CAR-T, dual- and multi-target CAR-T, armored CAR-T, and in vivo CAR-T approaches.
A Growing CAR-T R&D And Manufacturing Ecosystem
China has developed a CAR-T ecosystem spanning target discovery, plasmid and viral vector development, cell manufacturing, quality control, cold-chain logistics, clinical treatment, and payment models.
Quick Overview
Learn about approved products, eligibility assessment, treatment timing, and follow-up considerations for CAR-T cell therapy.
Approved Products And Indications
View detailsCompare targets, approved indications, and publicly listed product prices.
Ex Vivo Vs. In Vivo CAR-T
View detailsUnderstand how approved ex vivo CAR-T products differ from in vivo CAR-T approaches under study.
Pre-Treatment Assessment
View detailsAssessment considers diagnosis, target, prior treatment, organ function, infection, and performance status.
CAR-T Treatment Process And Estimated Timeline
View detailsReview medical record assessment, cell collection, manufacturing, lymphodepletion, infusion, and monitoring.
Recovery And Long-Term Follow-Up
View detailsUnderstand monitoring priorities and the need for longer-term follow-up after treatment.
Care Journey
- 01
Remote Enquiry And Initial Coordination
The coordination team supports initial communication and provides access to a designated secure channel for medical records.
- 02
Remote Specialist Assessment
The hospital and specialist team determine whether an on-site assessment is advised and what additional information is needed.
- 03
Travel Planning And Preparation
A dedicated coordinator assists with medical visa documents and coordinates flights, accommodation, an adult caregiver, and interpreting.
- 04
On-Site Testing And Multidisciplinary Assessment
The hospital completes the required assessments and confirms the next steps.
- 05
Hospital Assessment And Treatment
The treatment team determines the specific treatment arrangements.
- 06
Recovery And Continuity Of Care
After discharge, infection prevention, follow-up assessments, and long-term monitoring should follow the treatment center's plan.
Medical team
Review hospitals and specialists with relevant experience in this treatment. Availability, team composition, and admission arrangements must be confirmed with the receiving hospital.
Hospitals
Peking University Cancer Hospital
Beijing
Shen Lin’s team led early and pivotal clinical research on CLDN18.2-directed CAR-T therapy.
Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences
Tianjin
The hospital is home to the National Clinical Research Center for Blood Diseases and conducts integrated CAR-T and transplant research.
The First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou
Huang He’s team developed the Hangzhou Protocol for CAR-T followed by allogeneic hematopoietic stem cell transplantation.
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan
An early center for CAR-T clinical research, the hospital participated in product studies for pediatric and adolescent B-cell acute lymphoblastic leukemia (B-ALL).
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai
The hospital provides commercial CAR-T treatment and has published research involving Asian patients in China.
Zhongshan Hospital, Fudan University
Shanghai
The hospital supports screening, pathology review, and multidisciplinary assessment for patients being evaluated for approved CAR-T treatment for gastric or gastroesophageal junction cancer.
Frequently asked questions
How much should an international patient budget for CAR-T treatment in China?
Publicly listed prices for domestically approved CAR-T products are approximately USD 141,000–184,000 per dose, converted at CNY 7 = USD 1. International medical travelers generally do not have access to China’s basic medical insurance and should plan to self-pay. Testing, cell collection, hospitalization, lymphodepletion, bridging therapy, and adverse-event management are additional. Before traveling, obtain an itemized written estimate from the hospital; actual costs are subject to individual assessment.
When can I take an international flight after treatment?
There is no single timeline for all patients. The treating team must assess fitness to fly based on blood counts, infection status, neurological status, risk of acute toxicity, and access to medical care at the destination.
What happens if the disease returns after CAR-T treatment?
Based on the cause of relapse, changes in target expression, and the patient’s condition, the physician may assess CAR-T therapy against another target, antibody-based therapies, bispecific antibodies, chemotherapy, hematopoietic stem cell transplantation, or a clinical trial.
Do I need a family member with me during treatment?
An adult caregiver is usually recommended. Fever, low blood pressure, or changes in awareness or speech can occur after infusion and should be reported to the treating team immediately.
Can CAR-T treat every type of cancer?
No. Each approved product has specific requirements for cancer type, target expression, and prior treatment. The patient must meet the approved indication and be assessed by the treatment center.
Can CAR-T guarantee a cure?
No. Outcomes vary with cancer type, target, disease burden, previous treatment, and individual health. The treatment team explains the expected benefits and risks.
How should I compare hospitals and CAR-T products?
Compare approved indications, the hospital’s authorization to administer the product, the team’s experience with the cancer type and target, critical care and toxicity management, pathology and infection support, and long-term follow-up. Price alone should not determine your choice.
What records are needed before CAR-T treatment?
Requirements vary by product and treatment center. Commonly requested records include pathology reports, target testing, recent imaging or bone marrow studies, prior treatment records, recent laboratory results, infection screening, and records of any previous transplantation, major infections, or cardiopulmonary disease. Follow the receiving hospital’s instructions and the approved product information.
What are the main risks of CAR-T therapy?
Key risks include cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), infection, low blood counts, hypogammaglobulinemia, and secondary malignancies. The treatment team will explain the risks specific to your case and the approved product.
Detailed information
Approved Products And Indications
The following is representative information on NMPA-approved products. Indications are summarized and do not replace the official prescribing information or an assessment by the treatment center.
| Approval date | Product / brand | Target | Manufacturer | Approved indication summary | Estimated product price (USD)* |
|---|---|---|---|---|---|
| 2021-06 | Axicabtagene Ciloleucel InjectionYescarta | CD19 | Fosun Kite Biotechnology | Adults with relapsed or refractory large B-cell lymphoma; later expanded to include selected patients eligible for second-line treatment | USD 171,000 |
| 2021-09 | Relmacabtagene Autoleucel InjectionCarteyva | CD19 | JW Therapeutics | Relapsed or refractory large B-cell lymphoma, follicular lymphoma, and mantle cell lymphoma in adults | USD 184,000 |
| 2023-06 | Equecabtagene Autoleucel InjectionFucaso | BCMA | Nanjing IASO Biotechnology and Innovent Biologics | Adults with relapsed or refractory multiple myeloma that progressed after at least three prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent | USD 167,000 |
| 2023-11 | Inaticabtagene Autoleucel InjectionYORWIDA | CD19 | Juventas Cell Therapy | Adults with relapsed or refractory B-cell acute lymphoblastic leukemia; later expanded to include relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy | USD 143,000 |
| 2024-03 | Zevorcabtagene Autoleucel InjectionZevor-cel | BCMA | CARsgen Therapeutics and Huadong Medicine | Adults with relapsed or refractory multiple myeloma that progressed after at least three prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent | USD 164,000 |
| 2024-08 | Ciltacabtagene Autoleucel InjectionCarvykti | BCMA | Nanjing Legend Biotech and Janssen | Adults with relapsed or refractory multiple myeloma that progressed after at least three prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent | Not published |
| 2025-07 | Ranicabtagene Autoleucel InjectionHICARA | CD19 | Shanghai HRAIN Biotechnology | Adults with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy | Not published |
| 2025-11 | Puzolcabtagene Autoleucel InjectionPulidekai® | CD19 | Chongqing Precision Biotech | Patients aged 3–21 years with CD19-positive refractory or relapsed B-cell acute lymphoblastic leukemia; patients relapsing more than 12 months after first remission must have received salvage chemotherapy | Not published |
| 2026-06 | Satricabtagene Autoleucel InjectionKailimei® | CLDN18.2 | Kaixing Life Technology (Shanghai), a CARsgen subsidiary | CLDN18.2-positive, HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma after failure of at least two prior lines of therapy | USD 141,000 |
Product indications and eligibility should be confirmed against the latest NMPA approvals, official prescribing information, and the receiving hospital’s assessment.
Ex Vivo Vs. In Vivo CAR-T
At the time of writing, all nine CAR-T products approved in China use autologous cells manufactured ex vivo.
Conventional CAR T-Cell Therapy (Ex-Vivo Manufacturing)
A patient's T cells are collected, genetically modified, expanded, and quality-tested outside the body before being infused back into the patient.
In-Vivo CAR T-Cell Therapy
Delivery systems are being studied to generate CAR T cells directly in the body. The source identifies this as an early clinical-research approach, not routine NMPA-approved commercial treatment.
Pre-Treatment Assessment
Assessment considers the cancer type, target, prior lines of treatment, organ function, infection status, and performance status. The hospital confirms eligibility.
Hematologic Malignancies
Assessment may cover approved indications involving large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, multiple myeloma, and B-cell acute lymphoblastic leukemia. Eligibility depends on the specific product criteria.
- Relapsed or refractory large B-cell lymphoma
- Relapsed or refractory follicular lymphoma
- Relapsed or refractory mantle cell lymphoma
- Relapsed or refractory B-cell acute lymphoblastic leukemia
- Relapsed or refractory multiple myeloma
Solid-Tumor Indication
Assessment may be available for CLDN18.2-positive, HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma that has progressed after at least two prior lines of treatment.
- Advanced CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma meeting the approved criteria
CAR-T Treatment Process And Estimated Timeline
This is a reference timeline for international patients. Approximately 4–6 weeks may be needed in China; actual timing depends on manufacturing, the treatment center, and the patient’s condition.
Medical Record Review And Eligibility Assessment
The hospital reviews the diagnosis, target expression, prior treatments, and product-specific eligibility criteria.
On-Site Tests And Multidisciplinary Assessment
Assessment may include pathology review, tumor burden, organ function, infection, and performance status.
Leukapheresis For T-Cell Collection
Peripheral-blood T cells are collected.
CAR-T Cell Manufacturing
A qualified GMP facility performs T-cell separation, genetic modification, expansion, and quality testing before transport.
Bridging Therapy When Needed
The treatment team may arrange bridging therapy for patients with rapidly progressing disease.
Lymphodepleting Chemotherapy
The regimen is determined by the treatment team.
CAR-T Cell Infusion
CAR-T cells are infused intravenously according to the treatment center’s protocol.
Inpatient Monitoring
Monitoring focuses on cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), infection, and other adverse events.
Response Assessment And Long-Term Follow-Up
Follow-up examinations, response assessment, and long-term monitoring follow the treatment center's plan.
Recovery And Long-Term Follow-Up
There is no single timeline for all patients. The treatment team must assess fitness to fly based on blood counts, infection status, neurological status, risk of acute toxicity, and access to medical care at the destination.
What To Monitor After Treatment
- Fever, low blood pressure, or breathing difficulty
- Changes in consciousness, speech, writing, or behavior
- Infection and prolonged low blood counts
- Hypogammaglobulinemia
What To Monitor During Long-Term Follow-Up
- Long-term blood counts and immune recovery
- Delayed neurological symptoms
- Risk of secondary malignancies
